Pharsight

Nexletol generic

Nexletol is an anti-hyperlipidemia drug owned by Esperion Theraps Inc. This drug contains bempedoic acid and was first authorised for market use on 21 February, 2020. Nexletol has a total of 8 patents, 5 of which have expired.

When will Nexletol generic be available?

The last patent of Nexletol is set to expire on 19 June, 2040. This suggests the potential release of Nexletol generic around that date. Drug patent challenges against Nexletol can be filed from 22 February, 2024.

Nexletol uses

Nexletol can be used as an adjunct to diet and maximally tolerated statin therapy to lower LDL-C in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. bempedoic acid, the active ingredient in Nexletol, inhibits cholesterol synthesis, hence effectively reducing LDL-C levels.

Nexletol patent expiration

Nexletol, owned by Esperion Theraps Inc., has 8 patents. Five of these have already expired. The remaining patents will expire progressively, with the last one expiring on 19 June, 2040, potentially paving the way for the release of Nexletol generic. Below are the details of the patents:

Nexletol dosage

Want to ask something?